Holen Sie sich die Stockscreener-App
16.80
14.29%
-2.80
Schlusskurs vom Vortag:
$19.60
Offen:
$19.91
24-Stunden-Volumen:
192.03K
Relative Volume:
1.28
Marktkapitalisierung:
$529.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-16.54%
1M Leistung:
+5.93%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$16.36
$19.91
1-Wochen-Bereich:
$16.36
$21.58
52-Wochen-Spanne:
$13.88
$24.03
Evommune Inc Stock (EVMN) Company Profile
Firmenname
Evommune Inc
Sektor
Branche
Telefon
(650) 223-7745
Adresse
1841 PAGE MILL RD, PALO ALTO
Vergleichen Sie EVMN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
16.80 | 617.87M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Eingeleitet | Raymond James | Strong Buy |
| 2026-01-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-12-01 | Eingeleitet | Evercore ISI | Outperform |
| 2025-12-01 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-01 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Evommune Inc Aktie (EVMN) Neueste Nachrichten
Evommune (NYSE:EVMN) Trading Down 7.7%Here's What Happened - MarketBeat
Evommune (NYSE:EVMN) Shares Gap UpWhat's Next? - MarketBeat
Evommune: Buy Rating Driven by Upcoming Phase II Readouts and Broad Inflammatory Disease Pipeline Potential - TipRanks
Raymond James Initiates Coverage on EVMN with Strong Buy Rating - GuruFocus
HC Wainwright Comments on Evommune FY2025 Earnings - MarketBeat
Raymond James initiates Evommune stock with Strong Buy rating, $40 target - Investing.com Nigeria
Evommune participates in a conference call with William Blair - MSN
Evommune’s EVO756 Trial Targets High-Need Urticaria Market: What Investors Should Watch - TipRanks
Evommune stock initiated with Buy rating at H.C. Wainwright on urticaria potential - Investing.com Nigeria
This Spire Global Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Evommune (EVMN) Receives 'Buy' Rating from HC Wainwright & Co. | - GuruFocus
Evommune initiated with a Buy at H.C. Wainwright - TipRanks
Spire Global Receives Positive Initial Coverage; Check Out the Four Major Analyst Initiations for Tuesday - Bitget
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Globe and Mail
The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stock - The Business Journals
Evommune (NYSE:EVMN) Trading 5.3% HigherTime to Buy? - MarketBeat
Evommune and BillionToOne climb on trading debut - MSN
Evommune, Inc. (NYSE:EVMN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Evommune Director Makes Bold Move With Fresh Insider Buy - TipRanks
Hopfner buys Evommune (EVMN) shares worth $17,350 By Investing.com - Investing.com Nigeria
Hopfner buys Evommune (EVMN) shares worth $17,350 - Investing.com India
Evommune, Inc.(NYSE: EVMN) added to S&P TMI Index - marketscreener.com
Evommune (NYSE:EVMN) Shares Up 9.3% – What’s Next? - Defense World
Aktis Oncology files for US IPO as biotech listings rebound - Reuters
Evommune (EVMN) awards 100,000 stock options to its Chief Medical Officer - Stock Titan
Evommune Prepares For Key Mid-2026 Trial Readouts, Advances Inflammation Pipeline - RTTNews
Silicon Valley biotech firm expands to 43,000 square feet after going public - The Business Journals
Buy Rating for Evommune, Inc. Driven by EVO756’s Promising Phase II Trial Potential - TipRanks
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Evommune, Inc. (EVMN) and Eli Lilly & Co (LLY) - The Globe and Mail
These Bay Area companies are IPO contenders in 2026 - The Business Journals
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - BioSpace
Evommune, Inc.: Promising Pipeline and Strategic Trials Drive Buy Rating - TipRanks
CEO Pena Surrenders 28,138 Of Evommune Inc [EVMN] - TradingView — Track All Markets
Evommune, Inc. SEC 10-Q Report - TradingView — Track All Markets
EVMN: Net loss narrowed to $40.6M as license revenue grew and IPO proceeds extended cash runway into 2028 - TradingView — Track All Markets
Evommune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - marketscreener.com
EVMN: IPO proceeds and licensing revenue strengthen position ahead of key 2026 clinical readouts - TradingView — Track All Markets
Evommune (EVMN) Stock Trends and Sentiment 2025 - MarketBeat
Biopharma funding normalizes as 2025 outperforms post-pandemic lows - BioWorld MedTech
Evommune, Inc. (EVMN) analyst ratings, estimates and forecasts - Yahoo Finance UK
Evommune (NYSE:EVMN) Upgraded at Zacks Research - Defense World
Evommune (EVMN) Competitors and Alternatives 2025 - MarketBeat
Evommune (NYSE:EVMN) Research Coverage Started at Evercore ISI - Defense World
Evommune (NYSE:EVMN) Shares See Activity on Sector Research Shift - Kalkine Media
Evommune (NYSE:EVMN) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Evommune initiated with an Outperform at William Blair - MSN
Evommune initiated with an Overweight at Cantor Fitzgerald - MSN
Evommune, Inc. (EVMN) options chain - Yahoo Finance UK
Evommune, Inc.: Revenue and Earnings Analysts Forecasts Revisions | EVMN | US30054Y1073 - marketscreener.com
Evommune, Inc.: Target Price Consensus and Analysts Recommendations | EVMN | US30054Y1073 - marketscreener.com
Finanzdaten der Evommune Inc-Aktie (EVMN)
Es liegen keine Finanzdaten für Evommune Inc (EVMN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.73%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):